Eosinophilic Esophagitis, Pipeline Review, H2 2019 – Adare Pharmaceuticals Inc, Celgene Corp, Kyowa Kirin Co. Inc & Quorum Innovations LLC – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Eosinophilic Esophagitis – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 5 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Eosinophilic Esophagitis – Overview
  • Eosinophilic Esophagitis – Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Eosinophilic Esophagitis – Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Eosinophilic Esophagitis – Companies Involved in Therapeutics Development
  • Adare Pharmaceuticals Inc
  • Allakos Inc
  • Banner Life Sciences LLC
  • Calypso Biotech SA
  • Celgene Corp
  • DBV Technologies SA
  • Dr. Falk Pharma GmbH
  • EsoCap AG
  • GlaxoSmithKline Plc
  • Humanigen Inc
  • Kyowa Kirin Co Ltd
  • Morphic Holding Inc
  • Quorum Innovations LLC
  • RAPT Therapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Eosinophilic Esophagitis – Drug Profiles
  • AK-002 – Drug Profile
  • benralizumab – Drug Profile
  • budesonide – Drug Profile
  • budesonide ODT – Drug Profile
  • CALY-002 – Drug Profile
  • cendakimab – Drug Profile
  • dupilumab – Drug Profile
  • esomeprazole – Drug Profile
  • fluticasone propionate – Drug Profile
  • fluticasone propionate – Drug Profile
  • HGEN-005 – Drug Profile
  • mepolizumab – Drug Profile
  • mometasone furoate – Drug Profile
  • MR Beta7-1 – Drug Profile
  • MR Beta7-2 – Drug Profile
  • Qi-201 – Drug Profile
  • RNAi Gene Therapy for Asthma and Eosinophilic Esophagitis – Drug Profile
  • RPT-193 – Drug Profile
  • Viaskin Milk – Drug Profile
  • Eosinophilic Esophagitis – Dormant Projects
  • Eosinophilic Esophagitis – Product Development Milestones
  • Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/q44ouu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900